Table 2 Clinical trials of targeted immune cells
From: Immunosenescence: signaling pathways, diseases and therapeutic targets
Target cell | NCT number | Interventions | Conditions | Study title |
|---|---|---|---|---|
Hematopoietic stem cell | NCT03940586 | Drug: Letermovir oral granules Drug: Letermovir tablet Drug: Letermovir intravenous | Cytomegalovirus (CMV) infection | Letermovir Treatment in Pediatric Participants Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) |
NCT06484049 | Hematopoietic Stem Cell Transplantation | Hematopoietic stem cell transplantation | Prospective Observational Clinical Study on Changes in Cognitive Levels in Elderly Patients Before and After Hematopoietic Stem Cell Transplantation | |
NCT06769568 | Drug: reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia | Aplastic anemia | Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia | |
NCT06399107 | Genetic: Drug Product is administered by IV infusion following myeloablative conditioning with busulfan | Sickle cell disease | Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease (BAH243) | |
T cell | NCT05037669 | Biological: PACE CART19 | Acute lymphoblastic leukemia, Chronic lymphocytic leukemia | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma |
NCT05979363 | Biological: anti-BCMA CAR-T Drug: VRD-based regimen | Plasma cell leukemia | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia | |
T cell | NCT04093596 | Genetic: ALLO-715 Biological: ALLO-647 Drug: Fludarabine Drug: Cyclophosphamide Drug: Nirogacestat | Relapsed/Refractory Multiple Myeloma | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL) |
NCT00477321 | Drug: CYT 107 | HIV Infections, Lymphopenia | Safety Study of IL-7 in HIV-infected Patients (Inspire) | |
NCT01190111 | Biological: Interleukin-7 | HIV | Study on Interleukin-7 (CYT107) in HIV Patients (Inspire 2) | |
NCT00684008 | Drug: CYT107 – Recombinant glycosylated human interleukin 7. Drug: rhIL-7 (CYT107) | AML, CML, MDS | Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant | |
NCT01233921 | Biological: palifermin Other: flow cytometry Other: laboratory biomarker analysis Other: pharmacological study | Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer | |
NCT01746849 | Biological: Palifermin Biological: Lupron Procedure: peripheral blood stem cell transplantation Radiation: Total-Body Irradiation (TBI) Drug: Thiotepa Drug: Cyclophosphamide Drug: Degarelix | Non-Hodgkin’s lymphoma, Myelodysplastic syndrome, Multiple myeloma, Leukemia | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | |
B cell | NCT00863187 | Biological: rituximab | Lymphoma | Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With Rituximab |
NCT04146285 | Drug: BAT4406F | Neuromyelitis optica spectrum disorders | A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders | |
NK cell | NCT06161545 | Drug: N-803 Drug: pembrolizumab Biological: PD-L1 t-haNK cells | Stage II squamous cell carcinoma of the head and neck, stage III Squamous Cell Carcinoma of the Head and Neck, Stage IV Squamous Cell Carcinoma of the Head and Neck | embrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma |
NCT04646980 | Dietary Supplement: Biobran/MGN-3 Other: Placebo | Influenza-like Illness | Biobran/ MGN-3 Increases Innate Resistance and Reduces the Incidence of Influenza-like Illnesses | |
Macrophage | NCT03487679 | Other: Fasting | Fasting | Effects of Prolonged Fasting on Microbiome and HDL |
NCT01686568 | Drug: Omega-3 Drug: placebo | Insulin Resistance | Omega-3 Fatty Acids and Insulin Sensitivity | |
NCT00473876 | Drug: Metformin Drug: Matched Placebo (Capsules) | Congestive heart failure, Insulin resistance | Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction (TAYSIDE Trial) (TAYSIDE) | |
NCT01045512 | Drug: fluvastatin | Aging, Inflammation | The Role of the “Inflammatory/ Pathogen Burden” for Cardiac Ageing (AntiCardAgeing) | |
Endothelial cell | NCT04537884 | Drug: UBX1325 | Diabetic macular edema, Neovascular age-related macular degeneration | Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration |
NCT02494141 | Drug: Curcumin Other: Placebo | Polycystic kidney, Autosomal dominant | Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD | |
Neutrophil | NCT02441205 | Behavioral: High Intensity Interval training | Aging, Disease | Interval Training, Inflammation and Immune Function |
Dendritic cell | NCT03026244 | Dietary Supplement: Milk protein, prebiotics, vitamin D Dietary Supplement: Placebo product | Immunosenescence, Inflammation | Effect of Milk Protein and Prebiotics in Combination With Vitamin D on Innate Immunity in Elderly People |
Eosinophil | NCT02305940 | Drug: Doxycycline Drug: Placebo | Chronic obstructive pulmonary disease (COPD) | Effects of Long Term Antibiotic Therapy on Exacerbation Rate in Stable COPD Patients |
Basophil | NCT05346302 | Drug: Pneumovax 23 Drug: Typhim VI Other: Saline | Inflammatory Response | Persistent Readiness Through Early Prediction Immunization Study (PREP DOD) |
